Question · asked by 1 review
Tinzaparin vs placebo: Pain durationScale from: 1 to 7.
- Population
- people with sickle cell disease
- Intervention
- Tinzaparin
- Comparison
- placebo
- Outcome
- Pain durationScale from: 1 to 7.
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Tinzaparin vs placebo Pain durationScale from: 1 to 7. · people with sickle cell disease Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease (2015) · Cochrane Headline outcomes only | no estimate extracted | 1 study · 253 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease 2015 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.